- Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totalling more than $2 million for Vietnam
- On December 1, the company announced its nasal spray was registered for sale in Vietnam with a formal launch attended by clinicians, politicians and healthcare workers
- VIRALEZE works by slowing down the infection of host cells when applied to cells before and after exposure to a respiratory virus
- VIRALEZE is now available in Vietnamese hospitals, clinics, pharmacies and retail consumers via local medical distribution networks
- Starpharma is down a slight 0.40 per cent on the market with shares trading at $1.26
Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totalling more than $2 million for Vietnam.
On December 1, the company announced its nasal spray was registered for sale in Vietnam with the formal launch attended by clinicians, healthcare professionals, politicians and media representatives.
Starpharma’s VIRALEZE nasal spray contains antiviral agent SPL7013, which works by slowing down the infection of host cells when applied to cells before and after exposure to respiratory viruses.
From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.
CEO Jackie Fairley is delighted with the success already achieved.
“We are delighted that the launch of VIRALEZE in Vietnam was so successful and has already generated significant sales,” Dr Fairley commented.
“This demand is indicative of the significant need for products like VIRALEZE, which are complimentary to vaccines and other preventative strategies.”
VIRALEZE is now available in Vietnamese hospitals, clinics, pharmacies and retail consumers via local medical distribution networks.
Starpharma said it continues negotiations with potential commercial partners elsewhere in multiple countries in Europe, Asia, and the Middle East.
Starpharma was down a slight 0.40 per cent on the market, with shares trading at $1.26 at 12:21 pm AEDT.